MiMedx Group, Inc. Q2 2026 Earnings Recap

MDXG Q2 2026 July 31, 2026

Get alerts when MDXG reports next quarter

Shares declined 2.1% following Q2 results and acquisition news as investors likely digested ongoing challenges in wound care despite surgical growth and the transformational Sanara MedTech deal.

Earnings Per Share Miss

$-0.05 vs $-0.05 est.

-1.0% surprise

Revenue Beat

64362000 vs 63460400 est.

+1.4% surprise

Market Reaction

1-Day +3.39%

5-Day +5.08%

See MDXG alongside your other holdings

Add to your portfolio — free

Key Takeaways

Surgical revenue grew 15% year-over-year, continuing momentum from prior quarters.
Overall company revenue rose 9% sequentially from Q1 to Q2.
Wound care remains under pressure due to Medicare reimbursement changes causing market disruption.
The Sanara MedTech acquisition (~$35/share) will shift MiMedx's revenue mix to 75% surgical and 25% wound post-close.
Expected 2027 combined company revenue above $400 million with double-digit growth and adjusted EBITDA margin exceeding 20%, driven by $20 million in cost synergies.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MDXG on AllInvestView.